Mayo Clinic Laboratories > Gastroenterology > Pediatric GI > Hereditary testing

Hereditary testing

Individualized insights to improve outcomes

Our targeted testing for hereditary GI conditions can help oncologists understand their patients’ risk of developing certain illnesses, including some cancers, in children with a family history of the disease. Developed by Mayo Clinic experts and backed by genetic counselors, these evaluations use next-generation sequencing to evaluate genes with known disease associations for insights that propel personalized treatment for patients identified as having inherited syndromes.

Hereditary Test menu

Hereditary Hereditary

Hereditary

Key testing

  • HPANP | Hereditary Pancreatitis Gene Panel, Varies
    • Confirms clinical diagnosis of familial or hereditary pancreatitis in patients with chronic pancreatitis.
    • Identifies gene mutations that contribute to pancreatitis in an individual or family.
    • Identifies gene mutations to allow for predictive and diagnostic testing in family members.
  • CRCGP | Hereditary Gastrointestinal Cancer Panel, Varies
    • Establishes diagnosis of a hereditary gastrointestinal cancer syndrome or hereditary polyposis syndrome, which allows for targeted cancer surveillance based on associated risks.
    • Identifies genetic variants associated with increased risk for GI cancer and polyposis, allowing for predictive testing and appropriate screening of at-risk family members.
  • CHLGP | Cholestasis Gene Panel, Varies
    • Establishes a molecular diagnosis for patients with cholestasis.
    • Identifies variants within genes known to be associated with cholestasis, enabling predictive testing of at-risk family members.

Highlights

Targeted panel boosts accuracy of hereditary pancreatitis testing: Linda Hasadsri, M.D., Ph.D., and Huong T. Cabral, M.S., C.G.C.

Linda Hasadsri, M.D., Ph.D., and Huong T. Cabral, M.S., C.G.C., explain how Mayo Clinic Laboratories' targeted test panel facilitates accurate diagnosis of hereditary pancreatitis, which heightens the risk for pancreatic cancer. Test results can guide cancer monitoring for patients and their families.

Learn more
Test identifies Lynch syndrome for targeted cancer monitoring: Wei Shen, Ph.D., and Rhianna Urban, M.S., CGC

Wei Shen, Ph.D., and Rhianna Urban, M.S., CGC, explain how Mayo Clinic Laboratories' gene panel establishes a diagnosis of Lynch syndrome, which heightens the risk for several cancers. Test results can guide targeted cancer surveillance for patients and their families.

Learn more
Assay finds genetic cause of low bile flow: Devin Oglesbee, Ph.D.

Devin Oglesbee, Ph.D., explains how Mayo Clinic Laboratories' cholestasis gene panel identifies mutations that cause low flow of bile from the liver. Test results help guide treatment decisions that can prevent liver damage.

Learn more
INTERESTED IN LEARNING MORE?

Fill out the form below and one of our specialists will be in touch.